Actually, they look like have been doing ARDS studies for a while looking in one of their presos. Quite good results, so we should be expecting similar (though the studies were not for COV-19 ARDS). It gives more me more confidence the results of the 12 subject 'trial' will be typical of Rem-L. Just a matter of time now.
So if these guys have done ARDS trials before, makes we wonder if they have one up on MSB by not going for mortality as primary endpoint. A less predictable outcome compared to days on ventilator? I know we still have as a secondary endpoint but I have invested in too many biotechs to know it never sounds good when the headlines says 'missed primary endpoint'.
MSB Price at posting:
$3.23 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)